Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance

• Autores principales: Nick Evans (Autor), Ruslan Grygorash (Autor), Paul Williams (Autor), Andrew Kyle (Autor), Terrence Kantner (Autor), Ravindra Pathak (Autor), XiaoBo Sheng (Autor), Fabio Simoes (Autor), Hiteshri Makwana (Autor), Ricardo Resende (Autor), Elena de Juan (Autor), Alan Jenkins (Autor), David Morris (Autor), Aurelie Michelet (Autor), Frances Jewitt (Autor), Felicity Rudge (Autor), Nicolas Camper (Autor), Anaïs Manin (Autor), William McDowell (Autor), Martin Pabst (Autor), Antony Godwin (Autor), Mark Frigerio (Autor), Matthew Bird (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Antibody-drug conjugates (ADCs) have begun to fulfil their promise as targeted cancer therapeutics with ten clinical approvals to date. As the field matures, much attention has focused upon the key factors required to produce safe and efficacious ADCs. Recently the role that linker-payload reagent d...